Business Context and Reporting Period
Company: Neurogene Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: April 14, 2025
Reporting Period: Events occurring on April 14, 2025.
This filing reports two material corporate governance and capital structure events: an amendment to a shareholder agreement regarding director nomination rights and a share exchange transaction involving prefunded warrants.
Key Financial Metrics
Note: This Form 8-K does not contain financial statements, revenue, profit, cash flow, or debt metrics.
- Shares Outstanding (Post-Exchange): 14,262,066 shares of Common Stock.
- Prefunded Warrants Outstanding (Post-Exchange): 6,792,559 warrants.
- Warrant Exercise Price: $0.001 per share.
- Shares Exchanged: 667,500 shares of Common Stock exchanged for prefunded warrants.
Material Changes
Amendment to Letter Agreement (Item 1.01)
Neurogene Inc. amended its July 17, 2023 letter agreement with Baker Bros. Advisors LP (BBA). The threshold for BBA to nominate one person for election as a director was increased from a minimum of 12.5% to 14.9% of the Company's then-outstanding voting common stock.
Share Exchange Transaction (Item 8.01)
The Company entered into an exchange agreement with certain existing stockholders to exchange 667,500 shares of Common Stock for prefunded warrants to purchase 667,563 shares. Key terms include:
- Beneficial Ownership Limitation: Holders cannot exercise warrants if it results in beneficial ownership exceeding 4.99% of outstanding shares, unless they provide 61 days' notice to increase the limit up to 19.99%.
- Regulatory Status: Issued without registration under Section 3(a)(9) of the Securities Act of 1933.
- Closing Date: Expected on or about April 14, 2025.
Guidance, Outlook, and Risks
Management Commentary: The filing contains no forward-looking guidance, revenue outlook, or management commentary regarding future operations.
Risks and Contingencies: The filing highlights the structural change in director nomination rights for BBA and the dilution mechanics associated with the prefunded warrants, specifically the beneficial ownership limitations that may restrict immediate exercise of the warrants.
Investor Verification Checklist
- Verify the exact number of shares outstanding and the impact of the 667,500 share exchange on total dilution.
- Confirm the current beneficial ownership percentage of Baker Bros. Advisors LP relative to the new 14.9% nomination threshold.
- Review the full text of the Side Letter Amendment (Exhibit 10.1) for additional covenants or conditions not summarized in the 8-K.
- Assess the liquidity impact of the prefunded warrants, noting the 4.99% beneficial ownership limitation on exercise.